Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar 27;78(13):976-84.
doi: 10.1212/WNL.0b013e31824d5846. Epub 2012 Feb 29.

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

S D Silberstein  1 , D W Dodick, A S Lindblad, K Holroyd, M Harrington, N T Mathew, D Hirtz; Chronic Migraine Treatment Trial Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

S D Silberstein et al. Neurology. .

Abstract

Objective: To assess the efficacy and safety of adding propranolol to topiramate in chronic migraine subjects inadequately controlled with topiramate alone.

Methods: This was a double-blind, placebo-controlled, randomized clinical trial conducted through the National Institute of Neurological Disorders and Stroke Clinical Research Collaboration, expected to randomize 250 chronic migraine subjects inadequately controlled (≥10 headaches/month) with topiramate (50-100 mg/day) to either propranolol LA (long acting) (240 mg/day) or placebo. Primary outcome was 28-day moderate to severe headache rate reduction at 6 months (weeks 16 to 24) compared with baseline (weeks -4 to 0).

Results: A planned interim analysis was performed after 48 sites randomized 171 subjects. The data and safety monitoring board recommended ending the trial after determining that it would be highly unlikely for the combination to result in a significant reduction in 28-day headache rate compared with topiramate alone if all 250 subjects were randomized. No safety concerns were identified. At study closure, 191 subjects were randomized. The 6-month reduction in moderate to severe 28-day headache rate and total 28-day headache rate for combination therapy vs topiramate alone was not significantly different: 4.0 vs 4.5 days (moderate to severe 28-day headache rate; p = 0.57) and 6.2 vs 6.1 days (total 28-day headache rate; p = 0.91).

Conclusions: This study does not provide evidence that the addition of propranolol LA to topiramate adds benefit when chronic migraine is inadequately controlled with topiramate alone.

Classification of evidence: This study provides Class II evidence that propranolol LA, added to topiramate, is ineffective in chronic migraine patients who fail topiramate monotherapy.

PubMed Disclaimer

Figures

Figure
Figure. Subject eligibility and follow-up for the Chronic Migraine Treatment Trial
*Three-month and 6-month follow-up is based on any required follow-up data provided (e.g., diary or questionnaires).
See this image and copyright information in PMC

Comment in

References

    1. Dodick D. Clinical practice: chronic daily headache. N Engl J Med 2006;354:158–165 - PubMed
    1. Friedank-Mueschenborn E, Fox AW. Cusums to measure chronic daily headache. Headache 2006;46:110–114 - PubMed
    1. Stovener LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193–210 - PubMed
    1. Coeytaux RR, Linville JC. Chronic daily headache in a primary care population: prevalence and headache impact test scores. Headache 2007;47:7–12 - PubMed
    1. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742–746 - PubMed

Publication types